Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for April 27, 2026, to review and approve the group’s unaudited financial results for the three months ended March 31, 2026. The announcement signals the upcoming release of the company’s first-quarter performance, which will provide investors and other stakeholders with an early view of its financial and operational trajectory for the year.
The board, chaired by Mr. Xiong Jun and comprising executive, non-executive and independent non-executive directors, will oversee the approval of these results in Shanghai. The timing of the meeting aligns with standard disclosure practices on the Hong Kong market and suggests the company is preparing to update the market on recent business developments and financial health.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong under stock code 1877. The group focuses on the research, development and commercialization of innovative therapies, positioning itself within China’s rapidly developing biotech and pharmaceutical sector.
Average Trading Volume: 3,778,716
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$43.32B
See more data about 1877 stock on TipRanks’ Stock Analysis page.